Business Monitor International


Belgium Pharmaceuticals & Healthcare Report

Published 04 September 2014

  • 114 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Belgium Pharmaceuticals & Healthcare Report

BMI View:   Multinational firms find Belgium to be an attractive investment destination as a European hub for clinical trials, new drug development and niche research. Even though per capita spending on pharmaceuticals is relatively high, it is subjected to continual downward pressure from Eastern Europe and Asia, which translates into growth opportunities for generic drugs. However, prescribers' brand loyalty, pay-to-delay deals, the near-universal unpopularity of commodity generics and a lack of perfect competition in the pharmaceutical sector constitute key impediments to further generic expansion.

Headline Expenditure Projections

  • Pharmaceuticals: EUR5.83bn (USD7.70bn) in 2013 to EUR5.79bn (USD7.76bn) in 2014; -0.62% in local currency terms and 0.9% in US dollar terms. Local currency forecast lower than in Q 3 14.

  • Healthcare: EUR41.79bn (USD55.17bn) in 2013 to EUR42.76bn (USD57.29bn) in 2014; +2.3% in local currency terms and 3.8% in US dollar terms. Local currency forecast in line with Q 3 14.

Risk/Reward Rating: 

In our Q414 Pharmaceutical Risk/Reward Ratings Belgium still ranks sixth out of the fifteen markets surveyed in the Western European region. It posted above or average scores in all indicators, with the exception of Country Risks.

Key Trends And Developments

  • In August 2014, UCB announced that it has joined the Multi-Sponsor Environment which allows the responsible sharing of clinical study data as a way to uncover new scientific knowledge or insights, advance medicine and ultimately benefit patients and other stakeholders. In line with its vision for patient-centered leadership, UCB is the first midcap biopharma company to join this new environment. The environment allows researchers to request access to anonymised patient level data and supporting documents from clinical studies to conduct further research. UCB's policy on data sharing embraces the Principles for Responsible Clinical Trial Data Sharing released by the US and...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belgium 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018)
23
Generic Drug Market Forecast
24
Table: Generic Companies By Market Share, 2010
26
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belgium 2010-2018)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Belgium 2012-2018)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (Belgium 2012-2018)
33
Other Healthcare Data
34
Key Risks To BMI's Forecast Scenario
35
Macroeconomic Forecasts
36
Economic Analysis
36
Table: Belgium - Economic Activity
39
Industry Risk Reward Ratings
40
Western Europe Risk/Reward Ratings
40
Belgium Risk/Reward Ratings
45
Rewards
45
Risks
45
Market Overview
47
Industry Trends And Developments
49
Epidemiology
49
Public Health Developments
50
Healthcare Sector
51
Healthcare Insurance
52
Healthcare Financing
53
Medical Tourism
54
Research And Development
55
Table: R&D Investment By Chemical & Life Science Industries, 2005-2010
55
Clinical Trials
59
Regulatory Development
61
Pharmaceutical Advertising
62
Regulatory Developments
62
Intellectual Property Issues
63
Pricing Regime
64
Reimbursement Regime
65
Table: Reimbursements By Category, 2009
67
Table: Price Build-Up For OTC Medicines
69
Competitive Landscape
70
Pharmaceutical Sector
70
Recent Company Developments
71
Pharmaceutical Distribution
74
Table: Members Of AnGR, 2011
74
Pharmaceutical Retail Sector
75
Table: Members Of OPHACO, 2011
76
Company Profile
78
UCB Pharma
78
Solvay (Abbott)
86
Janssen Pharmaceutica
89
Omega Pharma
92
Galapagos (GSK)
96
GlaxoSmithKline
102
Pfizer
105
Novartis
108
Sanofi
110
Merck & Co
113
Demographic Forecast
115
Table: Belgium's Population By Age Group, 1990-2020 ('000)
116
Table: Belgium's Population By Age Group, 1990-2020 (% of total)
117
Table: Belgium's Key Population Ratios, 1990-2020
118
Table: Belgium's Rural And Urban Population, 1990-2020
118
Glossary
119
Methodology
121
Pharmaceutical Expenditure Forecast Model
121
Healthcare Expenditure Forecast Model
121
Notes On Methodology
122
Risk/Reward Ratings Methodology
123
Ratings Overview
124
Table: Pharmaceutical Risk/Reward Ratings Indicators
124
Indicator Weightings
125

The Belgium Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Belgium Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belgian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Belgium to test other views - a key input for successful budgeting and strategic business planning in the Belgian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Belgian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Belgium.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc